MPTP susceptibility in the mouse: Behavioral, neurochemical, and histological analysis of gender and strain differences

Behavior Genetics

Volumn 30, Issue 3, 2000, Pages 171-182

  Sedelis, Marco ^a   Hofele, Katja ^a   Auburger, Georg W ^a,b   Morgan, Sarah ^a   Huston, Joseph P ^a   Schwarting, Rainer K W ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

BALB c; Behavior; C57BL 6; Dopamine; MPTP; Parkinson's disease; Striatum; Substantia nigra

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIORAL SCIENCE; DISEASE SEVERITY; DOPAMINE BRAIN LEVEL; FEMALE; GENDER; GENETIC SUSCEPTIBILITY; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; MAZE TEST; MOUSE; NERVE DEGENERATION; NEUROCHEMISTRY; NONHUMAN; PARKINSON DISEASE; SEX DIFFERENCE; STRAIN DIFFERENCE; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; CORPUS STRIATUM; FEMALE; GENOTYPE; LOCOMOTION; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PARKINSONIAN DISORDERS; SPECIES SPECIFICITY; SUBSTANTIA NIGRA; TEGMENTUM MESENCEPHALI; TYROSINE 3-MONOOXYGENASE;

ANIMALIA;

EID: 0033749345     PISSN: 00018244     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1001958023096     Document Type: Article

References (52)

1. Different toxicity of N-methyl-4-phenyl- 1,2,5,6-tetrahydropyridine (MPTP) on the nigrostriatal and mesolimbic pathways
2. Tests for emotionality in rats and mice: A review
3. The effect of 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP) on striatal and limbic catecholamine neurones in white and black mice. Antagonism by monoamine oxidase inhibitors
4. Effects of MPTP on locomotor activity in mice
5. Experimental strategies for the genetic dissection of complex traits in animal models
6. Estrogen alters MPTP-induced neurotoxicity in female mice: Effects on striatal dopamine concentrations and release
7. Genetic variations in midbrain dopamine cell number: Parallel with differences in responses to dopaminergic agonists and in naturalistic behaviors mediated by central depaminergic systems
8. MPTP-induced behavioural and biochemical deficits: A parametric analysis
9. Role of heat shock proteins in MPTP-induced neurotoxicity
10. MPTP- and MPP(+)-induced effects on body temperature exhibit age- and strain-dependence in mice
11. Chemical neuroanatomy and the analysis of neuronal circuitry in the enteric nervous system
12. Dopamine transporter is required for in vivo MPTP neurotoxicity: Evidence from mice lacking the transporter
13. Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man
14. The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse
15. Correlation between the neostriatal content of the 1methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice
16. Neurotoxicity of the meperidine analogue N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurons in the mouse
17. Enhanced oxidative stress and altered antioxidants in brains of Bcl-2-deficient mice
18. The acute effect on levels of catecholamines and metabolites in brain, of a single dose of MPTP in 8 strains of mice
19. The mesolimbic dopaminergic pathway is more resistant than the nigrostriatal dopaminergic pathway to MPTP and MPP+ toxicity: Role of BDNF gene expression
20. MPTP produces differential oxidative stress and antioxidative responses in the nigrostriatal and mesolimbic dopaminergic pathways
21. Activation and lateralization of sensorimotor field for perioral biting reflex by intranigral GABA agonist and by systemic apomorphine in the rat
22. MPTP toxicity in relation to age, dopamine uptake and MAO-B activity in two rodent species
23. Striatal concentrations of vesicular monoamine transporters are identical in MPTP-sensitive (C57BL/6) and -insensitive (CD-1) mouse strains
24. Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice
25. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level
26. The use of a plus-maze to measure anxiety in the mouse
27. MPP+ induced substantia nigra degeneration is attenuated in nNOS knockout mice
28. Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice
29. The neurotoxin MPTP increases calbindin-D28k levels in mouse midbrain dopaminergic neurons
30. Difference in recovery patterns of striatal dopamine content, tyrosine hydroxylase activity and total biopterin content after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration: A comparison of young and older mice
31. A simple quantitative bradykinesia test in MPTP-treated mice
32. MPTP-induced decrease in motor activity in two strains of mice: Its reversal by different monoamine oxidase inhibitors (MAOIs)
33. Mechanisms of MPTP toxicity
34. Strain differences in systemic 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity in mice correlate best with monoamine oxidase activity at the blood-brain barrier
35. The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism
36. Low dopamine transporter mRNA levels in midbrain regions containing calbindin
37. Dopamine transporter mRNA levels are high in midbrain neurons vulnerable to MPTP
38. Short-term effects of ether, equithesin and droperidol/fentanyl on catecholamine and indolamine metabolism in the brain of the rat
39. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments
40. Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae
41. Behavioral and biochemical effects of nicotine in an MPTP-induced mouse model of Parkinson's disease
42. Observations on the prevalence of nest-building in non-breeding TO strain mice and their use of two nesting materials
43. Handedness in rats: Blockade of reaching behavior by unilateral 6-OHDA injections into substantia nigra and caudate nucleus
44. The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice
45. D3 dopamine receptor-deficient mouse: Evidence for reduced anxiety
46. Comparison of key steps in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in rodents
47. Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice
48. VMAT2 knockout mice: Heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity
49. Dopamine neurons from transgenic mice with a knockout of the p53 gene resist MPTP neurotoxicity
50. Histochemical, biochemical and behavioural consequences of MPTP treatment in C-57 black mice
51. Morphological, neurochemical, and behavioral characterizations associated with the combined treatment of diethyldithiocarbamate and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice